Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action

被引:48
作者
Cho, Sung Jin [4 ]
Jensen, Niels H. [1 ,2 ]
Kurome, Toru [4 ]
Kadari, Sudhakar [4 ]
Manzano, Michael L. [3 ]
Malberg, Jessica E. [3 ]
Caldarone, Barbara [3 ]
Roth, Bryan L. [1 ,2 ]
Kozikowski, Alan P. [4 ]
机构
[1] Univ N Carolina, Sch Med, Dept Pharmacol,Div Med Chem & Nat Prod, Comprehens Canc Ctr,Ctr Neurobiol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, NIMH Psychoact Drug Screening Program, Chapel Hill, NC 27599 USA
[3] Psychogenics Inc, Tarrytown, NY 10591 USA
[4] Univ Illinois, Drug Discovery Program, Dept Med Chem & Pharmacognosy, Coll Pharm M C781, Chicago, IL 60612 USA
关键词
SEROTONIN 5-HT2C RECEPTOR; PROTEIN-COUPLED RECEPTOR; CRYSTAL-STRUCTURE; WAY-163909; DISCOVERY; AGENTS; HALLUCINOGENS; ANTAGONISTS; DISORDER; OXIDASE;
D O I
10.1021/jm801354e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report here the design, synthesis, and pharmacological properties of a series of compounds related to tranylcypromine (9), which itself was discovered as a lead compound in a high-throughput screening campaign. Starting from 9, which shows modest activity as a 5-HT2C agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT2C agonists through iterative structural modifications. Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring. Among the tested compounds, several were potent and efficacious 5-HT2C receptor agonists with selectivity over both 5-HT2A and 5-HT2B receptors in functional assays. The most promising compound is 37, with 120- and 14-fold selectivity over 5-HT2A and 5-HT2B, respectively (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, respectively). In animal studies, compound 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.
引用
收藏
页码:1885 / 1902
页数:18
相关论文
共 56 条
[31]   PALLADIUM-CATALYZED CROSS-COUPLING REACTIONS OF ORGANOBORON COMPOUNDS [J].
MIYAURA, N ;
SUZUKI, A .
CHEMICAL REVIEWS, 1995, 95 (07) :2457-2483
[32]   Hallucinogens [J].
Nichols, DE .
PHARMACOLOGY & THERAPEUTICS, 2004, 101 (02) :131-181
[33]   5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents [J].
Nilsson, Bjorn M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (14) :4023-4034
[34]   SYNTHESIS AND PROPERTIES OF ASYMMETRIC POLYMERS .23. SYNTHESIS AND OPTICAL PROPERTIES OF ASYMMETRIC POLYAMIDES DERIVED FROM OPTICALLY ACTIVE CYCLIC DICARBOXYLIC ACIDS [J].
OVERBERGER, CG ;
SHIMOKAW.Y .
MACROMOLECULES, 1971, 4 (06) :718-+
[35]  
*PRESTW CHEM, 2006, PRESTW DRUG LIB
[36]   Crystal structure of the human β2 adrenergic G-protein-coupled receptor [J].
Rasmussen, Soren G. F. ;
Choi, Hee-Jung ;
Rosenbaum, Daniel M. ;
Kobilka, Tong Sun ;
Thian, Foon Sun ;
Edwards, Patricia C. ;
Burghammer, Manfred ;
Ratnala, Venkata R. P. ;
Sanishvili, Ruslan ;
Fischetti, Robert F. ;
Schertler, Gebhard F. X. ;
Weis, William I. ;
Kobilka, Brian K. .
NATURE, 2007, 450 (7168) :383-U4
[37]  
Rocha BA, 2002, J NEUROSCI, V22, P10039
[38]   Modeling structurally variable regions in homologous proteins with rosetta [J].
Rohl, CA ;
Strauss, CEM ;
Chivian, D ;
Baker, D .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 55 (03) :656-677
[39]   GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function [J].
Rosenbaum, Daniel M. ;
Cherezov, Vadim ;
Hanson, Michael A. ;
Rasmussen, Soren G. F. ;
Thian, Foon Sun ;
Kobilka, Tong Sun ;
Choi, Hee-Jung ;
Yao, Xiao-Jie ;
Weis, William I. ;
Stevens, Raymond C. ;
Kobilka, Brian K. .
SCIENCE, 2007, 318 (5854) :1266-1273
[40]   Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents [J].
Rosenzweig-Lipson, Sharon ;
Sabb, Annmarie ;
Stack, Gary ;
Mitchell, Paul ;
Lucki, Irwin ;
Malberg, Jessica E. ;
Grauer, Steve ;
Brennan, Julie ;
Cryan, John F. ;
Rizzo, Stacey J. Sukoff ;
Dunlop, John ;
Barrett, James E. ;
Marquis, Karen L. .
PSYCHOPHARMACOLOGY, 2007, 192 (02) :159-170